Skip to content

Nektar Therapeutics

US · NKTR #3017 by market cap Listed 1970
30.20 -2.34 -7.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 32.04 -1.54%
After-hours 30.20 0.00%
Overnight 32.54 0.00%
76.4830.2030.202026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NKTR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -52.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 19.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -236.8% Better than 5%
Net margin -297.1% Better than 4%
Return on equity -217.9% Better than 3%
Return on invested capital -87.5% Better than 3%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -59.2% Better than 3%
6-month return -54.7% Better than 6%
12-month return (ex latest month) -28.8% Better than 9%
Distance below 52-week high 72.3% Better than 5%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.0x Better than 86%
Debt to assets 30.6% Better than 40%
Interest coverage -4.9x Better than 17%
Free cash flow / net income 103.3% Better than 40%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 70.0% Better than 48%
Upside to average target 356.1% Better than 98%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -18.97%
1M -23.00%
3M -59.48%
6M -56.54%
YTD -28.57%
1Y -45.20%
3Y +287.18%
5Y -82.94%

Key statistics

Price & volume

Prev close
32.54
Open
31.66
Day range
30.13 - 32.35
Avg price
30.84
Volume
1.02M
Turnover
31.39M
Amplitude
6.82%
52-week range
30.13 - 109.00

Valuation

P/E
-3.10
P/E (TTM)
-4.88
P/B
1.22
EPS
-9.73
Net profit
-332.91M
Net assets
849.72M

Share structure

Market cap
1.03B
Float cap
864.00M
Shares out
34.21M
Float shares
28.61M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 0% of range
30.13 109.00

72.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-26.77M net over the window

Short interest

Shares short
6.77M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Nektar Therapeutics (NKTR)?

Nektar Therapeutics last traded at 30.20. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Nektar Therapeutics's market cap?

About 1.03B.

What is the P/E ratio of Nektar Therapeutics?

The trailing twelve-month P/E is -4.88. The Valuation tab shows it against the stock's own five-year range.

Does Nektar Therapeutics pay a dividend?

Nektar Therapeutics does not currently pay a regular dividend.

Is Nektar Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 137.75, which implies 356.1% upside from the current price. This is not investment advice.

What is Nektar Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Nektar Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

Nektar Therapeutics discussion 0 comments

Add a comment